Breaking News

Mundipharma Selects BioClinica’s OnPoint CTMS

By Kristin Brooks | January 28, 2014

Customizable solution designed to improve control and efficiency of trials

Mundipharma Research has selected BioClinica’s OnPoint CTMS (Clinical Trial Management System), for various aspects of its clinical trial management activities. OnPoint CTMS is web-based clinical trial management solution designed to improve control and efficiency of clinical trials, providing sponsors the ability to view and manage real-time operational performance.
OnPoint’s Office-Smart capabilities will be incorporated with Mundipharma’s Microsoft technologies and will allow users to access, update, and report on clinical trial data from within its existing Microsoft Office and SharePoint, a collaborative portal.
“We are very excited about Mundipharma Research’s decision to utilize the OnPoint approach to clinical trial management,” said Peter Benton, president of BioClinica’s eClinical Solutions. “Mundipharma Research is known for being a dynamic organization wholly dedicated to the research and development of highly effective and innovative medications. This requires supporting technologies that empowers users and makes them more productive. OnPoint’s customizable structure and robust reporting capabilities will accomplish this for Mundipharma Research while increasing collaboration and visibility.”

Related Compliance:

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials